A time-based and intratumoral proteomic assessment of a recurrent glioblastoma multiforme

Frontiers in Oncology

Volumn 6, Issue AUG, 2016, Pages

  de Aquino, Priscila F ^a   Carvalho, Paulo Costa ^b,c   Nogueira, Fábio C S ^d   da Fonseca, Clovis Orlando ^e   de Souza Silva, Júlio Cesar Thomé ^f   Carvalho, Maria da Gloria da Costa ^d   Domont, Gilberto B ^d   Zanchin, Nilson I T ^b   Fischer, Juliana de Saldanha da Gama ^b  

^a INSTITUTO LEÔNIDAS E MARIA DEANE   (Brazil)

^b INSTITUTO CARLOS CHAGAS   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^f Ipanema Federal Hospital   (Brazil)

Author keywords

Glioblastoma multiforme; ITRAQ; Molecular heterogeneity; Quantitative proteomics

Indexed keywords

HYDANTOIN; TEMOZOLOMIDE;

ADULT; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CASE REPORT; CLINICAL ASSESSMENT; DROWSINESS; DYSARTHRIA; FLUOROMETRY; GLIOBLASTOMA; HEADACHE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRACRANIAL HYPERTENSION; ION EXCHANGE CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEOMICS;

EID: 84990032848     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00183     Document Type: Article

References (59)

1. Park JK, Hodges T, Arko L, Shen M, Dello Iacono D, McNabb A, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 28:3838-43. doi:10.1200/JCO.2010.30.0582
2. Fadul C, Wood J, Thaler H, Galicich J, Patterson RH, Posner JB. Morbidity and mortality of craniotomy for excision of supratentorial gliomas. Neurology (1988) 38:1374-9. doi:10.1212/WNL.38.9.1374
3. Inda M-M, Bonavia R, Seoane J. Glioblastoma Multiforme: A Look Inside Its Heterogeneous Nature. Cancers (2014) 6:226-39. doi:10.3390/cancers6010226
4. Eder K, Kalman B. Molecular heterogeneity of glioblastoma and its clinical relevance. Pathol Oncol Res (2014) 20:777-87. doi:10.1007/s12253-014-9833-3
5. Fischer JSG, Carvalho PC, Canedo NHS, Goncalves KMS, Aquino PF, Almeida B, et al. Applications of formalin fixed paraffin-embedded tissue proteomics in the study of cancer. Austin Proteomics (2014) 1:1-7.
6. Fischer JSG, Canedo NHS, Goncalves KMS, Chimelli LMC, Franca M, Leprevost FV, et al. Proteome analysis of formalin-fixed paraffin-embedded tissues from a primary gastric melanoma and its meningeal metastasis: a case report. Curr Top Med Chem (2014) 14:382-7. doi:10.2174/1568026613666131204114218
7. Washburn MP, Ulaszek R, Deciu C, Schieltz DM, Yates JR. Analysis of quantitative proteomic data generated via multidimensional protein identification technology. Anal Chem (2002) 74:1650-7. doi:10.1021/ac015704l
8. Aquino PF, Fischer JSG, Neves-Ferreira AGC, Perales J, Domont GB, Araujo GDT, et al. Are gastric cancer resection margin proteomic profiles more similar to those from controls or tumors? J Proteome Res (2012) 11:5836-42. doi:10.1021/pr300612x
9. Aquino PF, Lima DB, de Saldanha da Gama Fischer J, Melani RD, Nogueira FCS, Chalub SRS, et al. Exploring the proteomic landscape of a gastric cancer biopsy with the shotgun imaging analyzer. J Proteome Res (2014) 13:314-20. doi:10.1021/pr400919k
10. Sottoriva A, Spiteri I, Piccirillo SGM, Touloumis A, Collins VP, Marioni JC, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A (2013) 110:4009-14. doi:10.1073/pnas.1219747110
11. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 3:1154-69. doi:10.1074/mcp.M400129-MCP200
12. da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, et al. Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas. Surg Neurol (2008) 70:259-67. doi:10.1016/j.surneu.2007.07.040
13. DA Fonseca CO, Teixeira RM, Silva JC, DE Saldanha DA, Gama Fischer J, Meirelles OC, et al. Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation. Anticancer Res (2013) 33:5625-31.
14. Fischer Jde S, Carvalho PC, Neves-Ferreira AG, da Fonseca CO, Perales J, Carvalho Mda G, et al. Anti-thrombin as a prognostic biomarker candidate for patients with recurrent glioblastoma multiform under treatment with perillyl alcohol. J Exp Ther Oncol (2008) 7:285-90.
15. Makarov A. Electrostatic axially harmonic orbital trapping: a high-performance technique of mass analysis. Anal Chem (2000) 72:1156-62. doi:10.1021/ac991131p
16. Carvalho PC, Lima DB, Leprevost FV, Santos MDM, Fischer JSG, Aquino PF, et al. Integrated analysis of shotgun proteomic data with PatternLab for proteomics 4.0. Nat Protoc (2015) 11:102-17. doi:10.1038/nprot.2015.133
17. Xu T, Park SK, Venable JD, Wohlschlegel JA, Diedrich JK, Cociorva D, et al. ProLuCID: an improved SEQUEST-like algorithm with enhanced sensitivity and specificity. J Proteomics (2015) 129:16-24. doi:10.1016/j.jprot.2015.07.001
18. Carvalho PC, Fischer JSG, Xu T, Cociorva D, Balbuena TS, Valente RH, et al. Search engine processor: filtering and organizing peptide spectrum matches. Proteomics (2012) 12:944-9. doi:10.1002/pmic.201100529
19. Fischer Jde S, Liao L, Carvalho PC, Barbosa VC, Domont GB, CarvalhoMda G, et al. Dynamic proteomic overview of glioblastoma cells (A172) exposed to perillyl alcohol. J Proteomics (2010) 73:1018-27. doi:10.1016/j.jprot.2010.01.003
20. Carvalho PC, Fischer JS, Chen EI, Domont GB, Carvalho MG, Degrave WM, et al. GO explorer: a gene-ontology tool to aid in the interpretation of shotgun proteomics data. Proteome Sci (2009) 7:6. doi:10.1186/1477-5956-7-6
21. Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The Reactome pathway Knowledgebase. Nucleic Acids Res (2016) 44:D481-7. doi:10.1093/nar/gkv1351
22. Zhang B, Chambers MC, Tabb DL. Proteomic parsimony through bipartite graph analysis improves accuracy and transparency. J Proteome Res (2007) 6:3549-57. doi:10.1021/pr070230d
23. Fortin Ensign SP, Mathews IT, Symons MH, Berens ME, Tran NL. Implications of Rho GTPase signaling in glioma cell invasion and tumor progression. Front Oncol (2013) 3:241. doi:10.3389/fonc.2013.00241
24. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 4:127s10. doi:10.1126/scitranslmed.3003854
25. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer (2012) 12:487-93. doi:10.1038/nrc3298
26. Parker NR, Khong P, Parkinson JF, Howell VM, Wheeler HR. Molecular heterogeneity in glioblastoma: potential clinical implications. Front Oncol (2015) 5:55. doi:10.3389/fonc.2015.00055
27. Chen H, Xu C, Jin Q, Liu Z. S100 protein family in human cancer. Am J Cancer Res (2014) 4:89-115.
28. Li C, Li S, Jia C, Yang L, Song Z, Wang Y. Low concentration of S100A8/9 promotes angiogenesis-related activity of vascular endothelial cells: bridges among inflammation, angiogenesis, and tumorigenesis? Mediators Inflamm (2012) 2012:248574. doi:10.1155/2012/248574
29. Huang N, Chen S, Deng J, Huang Q, Liao P, Wang F, et al. Overexpression of S100A9 in human glioma and in-vitro inhibition by aspirin. Eur J Cancer Prev (2013) 22:585-95. doi:10.1097/CEJ.0b013e328364f1c9
30. Li J, Fu Y, Zhao B, Xiao Y, Chen R. Myeloperoxidase G463A polymorphism and risk of lung cancer. Tumour Biol (2014) 35:821-9. doi:10.1007/s13277-013-1113-4
31. Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, et al. Association of myeloperoxidase with ovarian cancer. Tumour Biol (2014) 35:141-8. doi:10.1007/s13277-013-1017-3
32. London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res (1997) 57:5001-3.
33. Ding G, Liu F, Feng C, Xu J, Ding Q. [Association between the myeloperoxidase gene polymorphisms and the susceptibility to prostate cancer: a case-control study in a Chinese population]. Actas Urol Esp (2013) 37:79-82. doi:10.1016/j.acuro.2012.03.020
34. Rymaszewski AL, Tate E, Yimbesalu JP, Gelman AE, Jarzembowski JA, Zhang H, et al. The role of neutrophil myeloperoxidase in models of lung tumor development. Cancers (2014) 6:1111-27. doi:10.3390/cancers6021111
35. Glorieux C, Auquier J, Dejeans N, Sid B, Demoulin J-B, Bertrand L, et al. Catalase expression in MCF-7 breast cancer cells is mainly controlled by PI3K/Akt/mTor signaling pathway. Biochem Pharmacol (2014) 89:217-23. doi:10.1016/j.bcp.2014.02.025
36. Glorieux C, Dejeans N, Sid B, Beck R, Calderon PB, Verrax J. Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy. Biochem Pharmacol (2011) 82:1384-90. doi:10.1016/j.bcp.2011.06.007
37. Tsai J-Y, Lee M-J, Dah-Tsyr Chang M, Huang H. The effect of catalase on migration and invasion of lung cancer cells by regulating the activities of cathepsin S, L, and K. Exp Cell Res (2014) 323:28-40. doi:10.1016/j.yexcr.2014.02.014
38. Eckschlager T, Adam V, Hrabeta J, Figova K, Kizek R. Metallothioneins and cancer. Curr Protein Pept Sci (2009) 10:360-75. doi:10.2174/138920309788922243
39. Mehrian-Shai R, Yalon M, Simon AJ, Eyal E, Pismenyuk T, Moshe I, et al. High metallothionein predicts poor survival in glioblastoma multiforme. BMC Med Genomics (2015) 8:68. doi:10.1186/s12920-015-0137-6
40. Takahashi S. Molecular functions of metallothionein and its role in hematological malignancies. J Hematol Oncol (2012) 5:41. doi:10.1186/1756-8722-5-41
41. Gu G, Cheng W, Yao C, Yin J, Tong C, Rao A, et al. Quantitative proteomics analysis by isobaric tags for relative and absolute quantitation identified Lumican as a potential marker for acute aortic dissection. J Biomed Biotechnol (2011) 2011:920763. doi:10.1155/2011/920763
42. Kao WW-Y, Funderburgh JL, Xia Y, Liu C-Y, Conrad GW. Focus on molecules: Lumican. Exp Eye Res (2006) 82:3-4. doi:10.1016/j.exer.2005.08.012
43. Kelemen LE, Couch FJ, Ahmed S, Dunning AM, Pharoah PD, Easton DF, et al. Genetic variation in stromal proteins decorin and lumican with breast cancer: investigations in two case-control studies. Breast Cancer Res (2008) 10:R98. doi:10.1186/bcr2201
44. Naito Z. Role of the small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. J Nippon Med Sch (2005) 72:137-45. doi:10.1272/jnms.72.137
45. Farace C, Oliver JA, Melguizo C, Alvarez P, Bandiera P, Rama AR, et al. Microenvironmental modulation of decorin and lumican in temozolomide-resistant glioblastoma and neuroblastoma cancer stem-like cells. PLoS One (2015) 10:e0134111. doi:10.1371/journal.pone.0134111
46. Fukuda ME, Iwadate Y, Machida T, Hiwasa T, Nimura Y, Nagai Y, et al. Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res (2005) 65:5190-4. doi:10.1158/0008-5472.CAN-04-4134
47. Garcia M, Platet N, Liaudet E, Laurent V, Derocq D, Brouillet J-P, et al. Biological and clinical significance of Cathepsin D in breast cancer metastasis. Stem Cells (1996) 14:642-50. doi:10.1002/stem.140642
48. Johnson MD, Torri JA, Lippman ME, Dickson RB. The role of cathepsin d in the invasiveness of human breast cancer cells. Cancer Res (1993) 53:873-7.
49. Berchem G, Glondu M, Gleizes M, Brouillet J-P, Vignon F, Garcia M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene (2002) 21:5951-5. doi:10.1038/sj.onc.1205745
50. Astorgues-Xerri L, Riveiro ME, Tijeras-Raballand A, Serova M, Neuzillet C, Albert S, et al. Unraveling galectin-1 as a novel therapeutic target for cancer. Cancer Treat Rev (2014) 40:307-19. doi:10.1016/j.ctrv.2013.07.007
51. Ito K, Stannard K, Gabutero E, Clark AM, Neo S-Y, Onturk S, et al. Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev (2012) 31:763-78. doi:10.1007/s10555-012-9388-2
52. Jung T-Y, Jung S, Ryu H-H, Jeong Y-I, Jin Y-H, Jin S-G, et al. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines. J Neurosurg (2008) 109:273-84. doi:10.3171/JNS/2008/109/8/0273
53. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem (2004) 37:512-8. doi:10.1016/j.clinbiochem.2004.05.012
54. Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko IV, et al. Aberrant signaling pathways in glioma. Cancers (2011) 3:3242-78. doi:10.3390/cancers3033242
55. Downward J. Targeting RAS and PI3K in lung cancer. Nat Med (2008) 14:1315-6. doi:10.1038/nm1208-1315
56. Prior IA, Lewis PD, Mattos CA. Comprehensive survey of Ras mutations in cancer. Cancer Res (2012) 72:2457-67. doi:10.1158/0008-5472.CAN-11-2612
57. Thomas NE, Edmiston SN, Alexander A, Groben PA, Parrish E, Kricker A, et al. Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma. JAMA Oncol (2015) 1:359-68. doi:10.1001/jamaoncol.2015.0493
58. Albert FW, Treusch S, Shockley AH, Bloom JS, Kruglyak L. Genetics of single-cell protein abundance variation in large yeast populations. Nature (2014) 506:494-7. doi:10.1038/nature12904
59. Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 12:323-34. doi:10.1038/nrc3261